Q1 2024 Earnings Summary
- BWXT's Medical business is poised for significant growth, as they are at the tail end of industrializing their Moly-99 product line and are focusing on commercialization. They are working through the final items with the FDA and there's strong market enthusiasm for the product. Additionally, BWXT is a key supplier of non-carrier-added Actinium, supporting multiple clinical trials, and is involved in strategic partnerships, such as with Fusion Pharmaceuticals, which was recently acquired for $2 billion. These developments could lead to a compelling valuation for BWXT's Medical business in the future.
- BWXT is expanding its Cambridge plant to meet rising demand in the commercial nuclear market, particularly for small modular reactors (SMRs). They have secured projects such as the Pickering life extension, which involves manufacturing 48 steam generators, and are expecting firm orders for SMR reactor pressure vessels in the next few months. This expansion positions BWXT to capitalize on a wave of demand from domestic and international markets.
- Despite industry challenges, BWXT is successfully managing labor pressures by hiring ahead of the industry, increasing utilization at their top component sites by almost 400 basis points year-over-year, and maintaining their guidance. This indicates operational strength and the ability to meet growing demand, particularly in the Naval Propulsion business where they are somewhat decoupled from shipyard delays and maintain a strong backlog due to the strategic priority of their products.
- Potential slowdown in Virginia class submarine production could negatively impact BWXT's future revenue. Analysts expressed concerns about the Virginia class being slowed down, and while BWXT's management stated they are somewhat decoupled from shipyard delays, prolonged reductions in production rates may affect the company's workload and backlog.
- Government Operations are experiencing margin pressure due to the ramp-up of new projects at lower margins. BWXT's adjusted EBITDA margin in the Government Operations segment declined by 200 basis points year-over-year in Q1 2024, partly because of onboarding inefficiencies and the ramp-up of cost-plus projects like Pele and DRACO, which are contributing at lower margins.
- Uncertainty in multiyear contract negotiations due to factors such as shipbuilding schedules, budget appropriations, and inflationary pressures on labor and materials. Management acknowledged that negotiating agreements with the customer is complex and that these factors blend into the discussions, potentially leading to delays or less favorable contract terms for BWXT.
-
Government Operations Margins
Q: What caused year-over-year margin pressure in Government Operations?
A: The 200 basis point decrease in Government Operations margins was partly due to last year's extraordinary performance , which included a one-time uplift from TSU performance fees and strong NOG volume. The other half resulted from ramping up new projects like the metal projects and initiatives within Advanced Technology, specifically Pele and DRACO, which come at lower margins. -
Multiyear Pricing Negotiations Delay
Q: Why is the multiyear pricing negotiation taking longer, and is there a bridge contract?
A: The negotiation has been delayed due to uncertainty around FY '24 appropriations and the defense supplemental, which affected funding availability. While the fuel part of the contract is complete , the rest has been operating under a bridge contract during the negotiations. Now that uncertainties are resolved, they are positioned to finalize the agreement. -
Medical Segment Update – Moly-99 and Lutetium
Q: What's the status of Moly-99 FDA approval and Lutetium progress?
A: For Moly-99, they are at the tail end of industrializing the product line and working through final items with the FDA. They have exercised their Target Delivery System and are pleased with product quality meeting all pharma requirements. For Lutetium, they expect to be in business sometime next year , and pharmaceutical companies will reference their product in FDA filings, making the process simpler. They are also setting up a processing line to make active pharmaceutical ingredients. -
Submarine Production Impact
Q: How does the slowed Virginia-class submarine production affect BWXT?
A: BWXT is somewhat decoupled from shipyards and sells reactors on their own schedule. The slowdown doesn't worry them due to their deep backlog and the strategic priority of the Virginia program. They note it's early in the budget process, and industrial capacity must increase to meet future needs. -
Labor Challenges
Q: Are labor challenges affecting BWXT's operations and ramp-up plans?
A: The labor environment is tough, but BWXT has reengineered their talent acquisition, hiring 10% of their workforce last year. While onboarding many people causes margin pressure due to training and overhead , they are handling the challenges and remain confident in their guidance. -
Cambridge Plant Expansion and SMR Demand
Q: When will elevated SMR demand start, and what does the Cambridge plant expansion enable?
A: Elevated demand is expected soon, with firm orders for reactor pressure vessels anticipated in the next few months. The expansion is needed due to a full existing plant capacity, including projects like Pickering, Bruce, and Darlington refurbishments, and new SMR activity. The additional capacity positions them for future demand waves, including international opportunities. -
CapEx Implications
Q: Will CapEx levels change due to the Cambridge expansion?
A: CapEx for this year may be at the upper end of their guidance, absorbing $10–20 million for the Cambridge project. However, they expect to offset this with strong operating cash flows. It's too early to discuss next year's CapEx, but they don't foresee major changes, and the project fits within their normal budget. -
Pickering Refurbishment Project
Q: Is BWXT's content roughly 10% of Pickering's project cost, and when will ordering begin?
A: While unable to specify percentage of total project cost, the opportunity is similar in scale to the Bruce reactors, with a $1 billion opportunity including steam generators, feeders, and heat exchangers. Long-lead material ordering could begin in the near term as discussions with the customer progress. -
Update on Romania Project
Q: What's the status of the Romania project and order timing?
A: The project is moving forward with export financing in place. Meaningful impact on BWXT is expected in 2 to 3 years, as schedules are being established and business alignment is underway. -
Fusion Acquisition Implications
Q: Thoughts on Fusion being acquired for $2 billion, and implications for BWXT's Medical business?
A: BWXT views it as a solid acquisition, affirming their strategy. They collaborate with Fusion and see value in their product and supply chain knowledge. While BWXT is not in the drug business, they are a key part of the ecosystem and believe their medical business could have compelling valuation when targets are met.